Axsome Therapeutics Financial Results Announcement
Axsome Therapeutics, Inc. (NASDAQ: AXSM), recognized for its pioneering work in treating central nervous system (CNS) disorders, has officially announced its schedule for disclosing financial results pertaining to the second quarter of 2025. The much-anticipated report is set for Monday, August 4, 2025, prior to the opening of the U.S. financial markets.
Details of the Conference Call
In conjunction with the financial results announcement, Axsome management will host a conference call at 8:00 a.m. Eastern Time to discuss the organization's performance and provide essential updates regarding its ongoing business initiatives.
Participating in the Call
To join the live conference call, participants can dial (877) 405-1239 for toll-free domestic access or +1 (201) 389-0851 for international callers. Additionally, a live webcast will be available on the "Webcasts & Presentations" section of the Investors tab on the company's website. This presentation will also be accessible for replay for approximately 30 days following the live event.
About Axsome Therapeutics
Axsome Therapeutics is dedicated to transforming the landscape of CNS treatment. With a vision to address critical gaps in care, the company develops innovative products that embrace novel mechanisms of action. Their cutting-edge neuroscience portfolio includes FDA-approved therapies that target major depressive disorder, excessive daytime sleepiness associated with narcolepsy, obstructive sleep apnea, and migraine management. Notably, Axsome is advancing several late-stage development programs that aim to combat serious neurological and psychiatric disorders affecting over 150 million individuals in the United States.
Commitment to Patients
The mission at Axsome Therapeutics extends beyond just innovations; it revolves around solving some of the most significant challenges faced in neurological health to ensure that patients and their families can thrive. Their relentless pursuit of breakthroughs underlines their commitment to enhancing patient outcomes.
Ongoing Projects and Research
The company has been at the forefront of research and development, and its portfolio includes treatments that have both innovated care and improved the quality of life for countless individuals. Axsome continues its efforts to provide updates on its ongoing projects and clinical trials, which are critical for expanding its product offerings and enhancing its market position.
Engagement with Investors
As a part of its dedication to transparency and fostering relationships with investors, Axsome consistently provides updates regarding its advancements and strategic initiatives. Investors are encouraged to stay informed through regular communications and public announcements.
Contact Information
For additional questions or inquiries, investors can contact:
Mark Jacobson
Chief Operating Officer
(212) 332-3243
mjacobson@axsome.com
Darren Opland
Director, Corporate Communications
(929) 837-1065
dopland@axsome.com
Frequently Asked Questions
When will Axsome Therapeutics report its Q2 2025 financial results?
Axsome Therapeutics will report its Q2 2025 financial results on August 4, 2025.
What is the timing for Axsome's conference call?
The conference call will occur at 8:00 a.m. Eastern Time following the financial results announcement.
How can I access the conference call?
You can join the conference call by dialing (877) 405-1239 or +1 (201) 389-0851. A live webcast will also be available on their website.
What areas does Axsome Therapeutics focus on?
Axsome Therapeutics is focused on developing treatments for CNS disorders, including major depressive disorder and sleep-related conditions.
Where can I find more information about Axsome Therapeutics?
Further details can be found on their official website or by contacting their investor relations team.
